1887
Volume 2014, Issue 1
  • ISSN: 2305-7823
  • EISSN:
Preview this article:
Zoom in
Zoomout

Response to ‘Lack of reversibility for NOACs’, Page 1 of 1

| /docserver/preview/fulltext/gcsp/2014/1/gcsp.2014.2-1.gif

There is no abstract available for this article.
Use the preview function to the left.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2014.2
2014-06-01
2020-08-14
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2014/1/gcsp.2014.2.html?itemId=/content/journals/10.5339/gcsp.2014.2&mimeType=html&fmt=ahah

References

  1. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013; 34:27:20942106.
    [Google Scholar]
  2. van Ryn J, Litzenburger T, Gan G, Coble K, Schurer J. In Vitro Characterization, Pharmacokinetics and Reversal of Supratherapeutic Doses of Dabigatran-Induced Bleeding in Rats by a Specific Antibody Fragment Antidote to Dabigatran. Stroke. 2013; 44::AWP261.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2014.2
Loading
  • Article Type: Letter
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error